The IPO Buzz: Attovia Prices Upsized IPO at $17 – Top – & Stock Up 29 Percent in NASDAQ Debut
Attovia Therapeutics (ATTO), a Phase 1 biotech developing drugs to treat chronic itching and IBD, priced its IPO at $17.00 – the top of its range, as expected – and sold 17 million shares – matching the IPO’s upsized terms disclosed this morning – to raise $289 million on Tuesday night, Aug. 4, 2026. At pricing, Attovia had a market cap of $731.49 million. Attovia Therapeuticsâ€..
Read more August 4, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Attovia Therapeutics | ATTO | 17.0 | $ 289.0 mil | 8/5/2026 Priced | S/O | S/O |
| TCGX Acquisition (Stock-Only) | TCGX | 7.5 | $ 75.0 mil | 8/5/2026 Priced | S/O | S/O |
| Braveheart Bio | BRVE | 21.3 | $ 382.5 mil | 8/6/2026 Priced | S/O | S/O |
Last 100 IPOs - August 5, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 58 |
| Number Down: | 38 |
| Number Unchanged: | 4 |
| Percentage Change From Issue Price: | 7.48% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - August 5, 2026
| Number of IPOs priced (Excluding 136 units) : | 106 |
| Number Up: | 60 |
| Number Down: | 42 |
| Number Unchanged: | 4 |
| Total Return From Issue Price: | 6.89% |
| The Nasdaq Composite Index YTD % Change | 35.22% |